The US Food and Drug Administration (FDA) has approved Idvynso, a once‑daily tablet for adults living with HIV‑1 who already have their virus well controlled.
The new treatment is designed to replace an existing antiretroviral regimen in people whose viral load is suppressed, meaning HIV levels in the blood are below detectable limits.
For many people living with HIV, treatment is lifelong. New options that maintain viral control while reducing the number of drugs taken can make long‑term care simpler and potentially better tolerated.
How HIV treatment works today
HIV is treated with combinations of antiretroviral medicines that stop the virus from making copies of itself.
Modern therapy is highly effective and allows most people with HIV to live long, healthy lives, provided treatment is taken consistently.
Most current regimens use three drugs and often include an integrase strand transfer inhibitor, a class that blocks HIV from inserting its genetic material into human cells.
Single‑tablet combinations have become common, reducing pill burden and improving adherence.
What the FDA has approved
Idvynso is a single tablet taken once a day. It combines two antiviral drugs, doravirine and islatravir, at doses of 100 mg and 0.25 mg respectively.
The approval applies to adults who:
- Are already on a stable HIV treatment regimen
- Have had an undetectable viral load, defined as HIV‑1 RNA below 50 copies per millilitre
- Have no history of treatment failure
- Have no known drug‑resistant virus linked to doravirine
The tablet is not intended for people starting HIV treatment for the first time.
Evidence behind the decision
The FDA’s decision is based on two large clinical trials involving adults with well‑controlled HIV. Both were human studies designed to test whether switching to Idvynso was as effective as staying on existing therapy.
In Trial 052, a double‑blind study, participants either continued taking Biktarvy, a widely used three‑drug tablet, or switched to Idvynso. After 48 weeks, 1 per cent of participants in each group had a detectable viral load of 50 copies per millilitre or more.
In Trial 051, an open‑label study, participants either stayed on their usual oral antiretroviral therapy or switched to Idvynso. At 48 weeks, 1 per cent of those who switched to Idvynso had a detectable viral load, compared with 5 per cent of those who remained on their previous treatment.
In plain terms, the studies suggest that switching to Idvynso can maintain viral suppression as effectively as continuing standard therapy in carefully selected patients.
How the drugs work
Doravirine belongs to a class called non‑nucleoside reverse transcriptase inhibitors. It blocks an enzyme HIV needs to convert its genetic material into a form that can infect human cells.
Islatravir works at an earlier step in the same process, interfering with viral replication by preventing HIV from copying its genetic code.
By targeting the virus in complementary ways, the two drugs together suppress HIV without the need for a third agent.
Strengths and limits of the evidence
The trials were randomised and active‑controlled, which strengthens confidence in the results. However, they only included people with stable, well‑controlled HIV and excluded those with previous treatment failure or certain types of drug resistance.
This means the findings cannot be applied to everyone living with HIV. Long‑term safety beyond the trial period will also continue to be monitored through routine post‑approval surveillance.
What this means for people with HIV
For eligible patients, Idvynso offers another option to maintain viral suppression with a single daily tablet containing two drugs rather than three. It is also tenofovir‑free and does not include an integrase inhibitor, which may be relevant for people who cannot tolerate those medicines or wish to avoid them.
The drug is not suitable for use with strong CYP3A enzyme inducers, which can reduce its effectiveness, or alongside lamivudine or emtricitabine.
Importantly, this approval does not change general HIV treatment advice. Decisions about switching therapy should always be made with a specialist HIV clinician. Talk to your clinician if you have medical inquiries.
How it fits into current treatment choices
Over the past decade, HIV care has moved towards simpler, well‑tolerated regimens that support lifelong adherence. Two‑drug combinations are already used in some settings, but options without integrase inhibitors or tenofovir have been limited.
Idvynso adds to the range of maintenance therapies available, giving clinicians more flexibility when tailoring treatment to individual needs and medical histories.
Further data will be needed to understand how Idvynso performs over many years of use and in broader patient populations. Ongoing research will also monitor rare side effects and assess how the drug fits into real‑world care.
HIV treatment continues to evolve from a focus on survival to long‑term quality of life. The approval of Idvynso reflects steady progress in offering people living with HIV more choice, while maintaining the high standards of viral control that underpin modern HIV care.
The post FDA Approves New Once‑Daily HIV Tablet for People with Suppressed Virus first appeared on PP Health Malaysia.